and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP) has not been effective, Categoria 2, Patients with vegetable allergies due to sensitization to profilin and LTPs, were evaluated in a before-after study to assess changes in clinical reactivity to LTP (peach) and profilin (melon) and immunological changes after intervention with omalizumab.
Conditions
Brief summary
Clinical efficacy defined as an increase in the amounts of peach in patients allergic to LTP and melon in patients allergic to apple tolerated in PPO after 16 weeks of treatment with omalizumab.
Detailed description
Clinical efficacy defined as an increase in the amounts of at least 1 other food related to sensitisation to LTP (quantitative)., Clinical efficacy defined as an increase in the amounts of at least 1 more food related to sensitisation to profilin (quantitative)., Analysis of quality of life before and after treatment with omalizumab.
Interventions
DRUGOmlyclo 75 mg solution for injection in pre-filled syringe
Sponsors
Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy defined as an increase in the amounts of peach in patients allergic to LTP and melon in patients allergic to apple tolerated in PPO after 16 weeks of treatment with omalizumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical efficacy defined as an increase in the amounts of at least 1 other food related to sensitisation to LTP (quantitative)., Clinical efficacy defined as an increase in the amounts of at least 1 more food related to sensitisation to profilin (quantitative)., Analysis of quality of life before and after treatment with omalizumab. | — |
Outcome results
None listed